The Cannabis Venture Syndicate – This is quite possibly the first service of its kind ever made available. It allows you to access details on four to six private investment deals over the next 12 months. Each of these deals has the potential to return profits of 1,000% to 100,000%.
What is Cannabis Venture Syndicate?
Cannabis Venture Syndicate is a brand-new research service dedicated to bringing average investors four to six private investment deals over the next 12 months. This premiums service offers readers the chance to break into a market that only 0.1% of Americans ever step into. The arena of startup investing. Giving you the chance to stake your claim to the kind of money that lasts for generations.
This service comes from National Institute for Cannabis Investors
The National Institute for Cannabis Investors (NICI) is a global cannabis-investing news service. Investors can access it either by visiting their Website (nicinvestors.com), or by subscribing to their free daily newsletter, Cannabis Profits Daily.
With The Cannabis Venture Syndicate, You Can Enter the Ultra-Lucrative Arena of Private Investing.
Right here, right now, you’ve can enter an arena that only 0.1% of Americans ever step into.
The arena of startup investing.
A chance to stake your claim to the kind of money that lasts for generations.
That’s not an exaggeration.
You’ve already seen the outsized gains that are possible with public cannabis stocks…
But these gains pale in comparison to what those who invested privately in cannabis companies have earned.
In fact, once you start seeing the kind of returns that are available to private investors, you’ll never be the same again.
Let’s look at Canopy Growth as an example…
Investors that bought Canopy when it went public made enough to grow a $10,000 investment to $227,500. That’s an incredible return.
However, for private investors who were able to invest in Canopy just six months prior, that same $10,000 initial stake grew to over $1.2 million.
That’s over five time as much as a public investor enjoyed.
As the #1 resource for cannabis investors, hundreds of these types of deals come to us every year.
And we know that only a small number of these deals have the potential to be blockbuster, multi-billion dollar companies. We want to makes sure we get those few, top-tier deals, in front a select group of our readers.
Because we know these kinds of companies are the only way to turn a small stake into potentially millions of dollars.
Fact is, it’s our mission to show average folks new ways to tap into the unbelievable growth in this industry.
Because without a doubt, we believe the biggest returns can come from this kind of early-stage investing.
That’s why we’ve created The Cannabis Venture Syndicate…
This brand-new research service is dedicated to bringing average investors four to six private investment deals over the next 12 months.
Each of these deals has the potential to return profits of 1,000% to 100,000%.
But this is only the beginning…
As one of our subscribers, you’ll immediately gain access to countless resources that could help you become a successful private investor.
Make no mistake, we believe this rare opportunity is unlike anything you’ve ever seen – or ever will see – again.
Because once you start seeing the kind of returns that can be available to private investors, you’ll never be the same again.
Meet The National Institute for Cannabis Investors (NICI) Advisory Board
Danny Brody
VP, The Green Organic Dutchman
Danny Brody is the Vice President of Investor Relations at The Green Organic Dutchman Holdings Ltd. (TGOD). Danny has more than ten years of experience in finance and holds a Chartered Investment Manager (CIM) designation from the Canadian Securities Institute (CSI).
Before leading TGOD to the most successful IPO in cannabis history, he was previously the Director of Investor Relations at Emblem Cannabis, and took the company public through a highly successful IPO.
Danny spent eight years in the brokerage industry, where he specialized in fundraising, building and maintaining client portfolios, financial advising, marketing, business development, structuring, advanced due diligence, lead generation, and database management before making the switch to the cannabis industry.
Read Full Cannabis Ipo Insider Review Here
John Vardaman
Executive VP, Hypur Inc./ Co-Author, The Cole Memo
John Vardaman, III, is the Executive Vice President and General Counsel at Hypur Inc., which provides tech solutions for the banking and payments industries. John has 15 years of experience working as a senior government official on some of the most challenging issues facing the financial services industry. John was an Assistant Deputy Chief at the U.S. Department of Justice (DOJ), and served as Counsel to the Treasury Department. He played an instrumental role in devising the federal policy for enforcing the Bank Secrecy Act and anti-money laundering laws.
At the DOJ, he was actively involved in drafting the agency’s guidance regarding financial crimes related to state legalization of cannabis, and notably co-authored The Cole Memo. He was also instrumental in devising DOJ policy regarding the enforcement of laws governing the structuring of financial transactions.
Vardaman is a graduate of Vanderbilt University, and earned his law degree from Georgetown University.
Dr. Avtar Dhillon
Executive Chairman, Emerald Health Therapeutics/
Chairman, Cannabis Canada Association.
Dr. Avtar Dhillon is the Executive Chairman of Emerald Health Therapeutics, Inc. He also is the Chairman of the Advisory Board of Nemus Bioscience Inc. as well as its Executive Chairman.
Dr. Dhillon has more than 20 years of experience in building public companies through mergers and acquisitions, leading innovation in science, engineering and farming enterprises, securing government grants and NGO funding, and building intellectual property portfolios. Notably, he was an Executive Chairman at Inovio Pharmaceuticals, Inc. from 2009 to 2011, and CEO and President from 2001 to 2009.
Dr. Dhillon was elected first Board Chair of the Cannabis Canada Council, a national industry association for the cannabis sector. Dr. Dhillon holds a Bachelor of Science in Human Physiology and an M.D. from the University of British Columbia.
Jenn Larry
President of CBD Strategy Group
Jenn Larry is President of CBD Strategy Group. CBD Strategy is a communications, brand development, and design-focused firm built for the cannabis industry. Over the past 17 years, she’s worked across multiple sectors, including music, online gambling, pharmaceutical, tobacco, payments, technology, and consumer packaged goods.
Jenn previously worked as Vice President of Strategy and Operations for the Precision Communications Group. She was also the Strategic Planner – Digital Development at Ogilvy & Mather. These roles have allowed her to create and execute strategies and programs within emerging, disrupted, and regulated environments. She is well known for her ability to forecast trends, leverage business intelligence and lead change across organizations.
Dr. Michael Dor
Senior Medical Advisor, Israel Ministry of Health
Dr. Michael Dor is the Senior Medical Advisor at the Israeli Ministry of Health’s Medical Cannabis Unit. Dr. Dor has collaborated extensively with Israeli organic chemist Raphael Mechoulam, who is known as the “father of cannabis research” for his contributions to the field.
Dr. Dor has also served as the Head of the Hospitals Division and Deputy Director of the Health Management in the ministry, where he initiated the quality control and licensing process of the Hospitals and the Clinical services in Israel. He voluntarily started a clinic for uninsured refugees and a shelter for victims of human trafficking, for which he was awarded the Presidential Award in 2014 – the highest civilian honor in Israel.
After retiring from the Ministry, Dr. Dor took up his role with the Medical Cannabis Unit, where he’s introduced more indications and helped improve the process of approval for treatments. He’s also continued his work as a family physician, and teaches at Ariel University and Hadassah College as a senior lecturer. Dr. Dor graduated from Tel Aviv University and earned a Master’s degree from Harvard University’s Kennedy School of Government. He continues to work as a practicing physician.
Michael A. Robinson
Director of Venture Capital and Technology Research, Money Morning
Michael A. Robinson is a 35-year Silicon Valley veteran and one of the top technology financial analysts working today. Michael is a consultant, senior adviser, and board member for Silicon Valley venture capital firms. He was one of five people involved in early meetings for the $160 billion “cloud” computing phenomenon, and was with Dave DeWalt, CEO of McAfee, right before Intel acquired his company for $7.8 billion.
Michael is a regular guest and panelist on CNBC and Fox Business. He’s also a Pulitzer Prize-nominated writer and reporter. Michael is a contributor to Money Morning and writers regularly about cannabis industry investing in Strategic Tech Investor, the Nova-X Report and Radical Technology Profits publications. He’s also worked for The New York Times and The Wall Street Journal.
Ernie Tremblay
Biotech Investing Specialist, Money Morning
Ernie Tremblay has more than 25 years of experience in following and analyzing the latest developments in health, medicine, and related technologies. As a health editor and writer, Ernie has contributed to more than 100 publications on topics like diabetes, Alzheimer’s disease, arthritis, dermatology, and groundbreaking medical therapies for publishers like Prentice Hall, Harper Collins, and others. Through the years, he’s gained “insider” access to some of the world’s top medical professionals, including Nobel-caliber doctors the Yale School of Medicine’s Dr. Karel Liem, Jr., and Harvard Medical School’s Dr. William S. Beck.
Ernie contributes to Money Morning, and writes about biotech investing in his Biotech Insider Alert. He has a thorough understanding of the Food and Drug Administration (FDA) approval process, as well as the “hard science” behind new, experimental drugs and the market demand for them.
What do you get with your subscription?
When you secure your Charter membership to the Cannabis Venture Syndicate, you will be charged $4,950 each year for as long as you choose to stay a member. You may cancel at any time and no additional charges will be made.
Once you subscribe, you’ll immediately gain access to…
- Access to Up to Six Private Cannabis Deals over the Next 12 MonthsEvery time Michael Robinson or other National Institute of Cannabis Investors board members find an interesting new deal from a private cannabis company, they bring it to the team to vet.If the deal looks good, they’ll send members…
- A Video Pitch Deck Presentation from a company executive…
- A complete Due Diligence Package…
- A Deal Memo…
- And a Terms Sheet.
Due to the fast-moving nature of these private companies, all of these documents are delivered electronically via email.
And to help you get started as a private cannabis investor, You will also receive:
- Private Investing PrimerThis is a short book with the 12 most important lessons you need to know to start investing in private companies.It covers everything from building a deal flow and analyzing a pitch to understanding valuation and deal structure. It reviews the different kinds of deals and what kind of investors can participate in each.It also highlights the different rounds of private financing and their advantages and drawbacks.The Cannabis Venture Syndicate team will also keep you up to date on all the important developments on these deals with…
- Text Message AlertsWhenever a new deal is announced, I can also choose to be notified through my cell phone along with the email notifications. This extra layer of communication has been put in place to help ensure I never miss an opportunity.
- Monthly Investor UpdatesEvery month,you will receive an update on all the developments of the deals presented to the Cannabis Venture Syndicate. That way you can track updates and get the chance to participate in any follow-up rounds the companies may offer.
- Special Email AlertsReal-time updates on major advances, clinical trials or progress, mergers and acquisitions, and IPO progress.
You will also be given the opportunity to exchange ideas with fellow members via…
- Membership to the Cannabis Venture MastermindThis online Mastermind lets you create your own forums with fellow members where you can discuss all of the deals available and share more private-deal opportunities with each other.
- The Annual Cannabis Venture Syndicate RetreatYou will receive a free ticket to the National Institute of Cannabis Investors annual retreat. At this event, you can participate in a live Mastermind meeting just for the Cannabis Venture Syndicate. Here, you ’ll meet your fellow members and get to hear live, in-person pitches from startup founders.
